Australia markets closed

TAKEDA PHARMACEUTICAL CO LTD (0RN3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
- (-)
At close: 08:42AM GMT
Full screen
Previous closeN/A
OpenN/A
Bid0.00 x N/A
Ask0.00 x N/A
Day's rangeN/A - N/A
52-week rangeundefined - undefined
VolumeN/A
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721

    OSAKA, Japan & CAMBRIDGE, Mass., December 21, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.1

  • Business Wire

    Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis

    OSAKA, Japan, December 17, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of intravenous (IV) vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), and have had an inadequat

  • Business Wire

    Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021

    CAMBRIDGE, Mass., December 13, 2021--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) ("Takeda") today announced the presentation of nine company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia and virtually. The abstracts span Takeda’s extensive hematology portfolio and research and development (R&D) pipeline, featuring data on multiple products and investigational candidates, supporting Takeda’s c